Quick Answer
Eloxx Pharmaceuticals, Inc. reported Cash and Equivalents of $4.79 million for fiscal year 2025.
Eloxx Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.79M | +4210.8% |
| 2024 | $111.0K | -90.2% |
| 2023 | $1.13M | -94.1% |
| 2022 | $19.21M | -54.6% |
| 2021 | $42.27M | +71.3% |
| 2020 | $24.67M | +9.7% |
| 2019 | $22.49M | -53.7% |
| 2018 | $48.61M | +102.1% |
| 2017 | $24.05M | +72341.1% |
| 2017 | $33.2K | -98.5% |
| 2016 | $2.21M | +172.8% |
| 2016 | $810.8K | -40.8% |
| 2015 | $1.37M | -58.9% |
| 2015 | $3.33M | +92.0% |
| 2014 | $1.74M | -71.6% |
| 2014 | $6.11M | +281.4% |
| 2013 | $1.60M | -19.9% |
| 2012 | $2.00M | -44.6% |
| 2011 | $3.61M | -55.0% |
| 2010 | $8.03M | — |
| 1998 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $4.78M | -80.6% | +10.3% |
| June 30, 2023 | $4.33M | -85.6% | -11.7% |
| March 31, 2023 | $4.90M | -87.7% | -74.5% |
| December 31, 2022 | $19.21M | -54.6% | -21.8% |
| September 30, 2022 | $24.55M | -53.2% | -18.3% |
| June 30, 2022 | $30.05M | -47.0% | -24.4% |
| March 31, 2022 | $39.77M | +117.9% | -5.9% |
| December 31, 2021 | $42.27M | +71.3% | -19.4% |
- Eloxx Pharmaceuticals, Inc. showed an increase of +4210.8% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Eloxx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: